title: Increase in interleukin-8 production from circulating neutrophils upon antibiotic therapy in cystic fibrosis patients.
abstract: BACKGROUND
  It is not known whether antibiotic therapy for lung disease in cystic fibrosis (CF) has an influence on circulating polymorphonuclear neutrophil (PMN) function and apoptosis.
  
  
  METHODS
  Blood PMNs were obtained from 14 CF patients before and after antibiotic treatment for an acute exacerbation, and from 10 healthy controls. PMNs were evaluated for production of reactive oxygen species (ROS) by spectrophotometry, of cytokines in the conditioned medium by ELISA, and apoptotic response by cytofluorimetry.
  
  
  RESULTS
  ROS and interleukin (IL)-8 were produced at higher levels by CF PMNs pre-therapy than control PMNs under basal conditions. IL-8 levels further increased after therapy. Early apoptotic response was higher in CF PMNs pre-therapy than in control PMNs, and this pattern did not change after antibiotic treatment.
  
  
  CONCLUSIONS
  Circulating PMNs are primed in CF acute patients. Further studies are needed to consider PMN-produced IL-8 as a biomarker to evaluate response to antibiotic therapy in CF patients.
authors.affiliation: Department of Biomedical Sciences and Human Oncology, Section of General Pathology, University of Bari, Bari, Italy.
authors.forename: Pasqualina
authors.initials: P
authors.lastname: Montemurro
authors.forename: Maria A
authors.initials: MA
authors.lastname: Mariggiò
authors.forename: Giovanna
authors.initials: G
authors.lastname: Barbuti
authors.forename: Amalia
authors.initials: A
authors.lastname: Cassano
authors.forename: Alessandra
authors.initials: A
authors.lastname: Vincenti
authors.forename: Gabriella
authors.initials: G
authors.lastname: Serio
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Guerra
authors.forename: Anna
authors.initials: A
authors.lastname: Diana
authors.forename: Teresa
authors.initials: T
authors.lastname: Santostasi
authors.forename: Angela
authors.initials: A
authors.lastname: Polizzi
authors.forename: Ruggiero
authors.initials: R
authors.lastname: Fumarulo
authors.forename: Valeria
authors.initials: V
authors.lastname: Casavola
authors.forename: Antonio
authors.initials: A
authors.lastname: Manca
authors.forename: Massimo
authors.initials: M
authors.lastname: Conese
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000276:immunology; D015415:Biomarkers / Q000378:metabolism; D002648:Child; D003550:Cystic Fibrosis / Q000276:immunology* / Q000382:microbiology; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006801:Humans; D016209:Interleukin-8 / Q000276:immunology* / Q000378:metabolism; D008297:Male; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D010865:Pilot Projects; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D055732:Pulmonary Aspergillosis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D017382:Reactive Oxygen Species / Q000378:metabolism; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D015415:Biomarkers; C508606:CXCL8 protein, human; D016209:Interleukin-8; D017382:Reactive Oxygen Species